Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 26 2025
0mins
Should l Buy GLMD?
Source: PRnewswire
Financial Performance: Galmed Pharmaceuticals reported a net loss of approximately $2.0 million for Q3 2025, with cash and cash equivalents totaling about $19.2 million, an increase from $15.4 million at the end of 2024.
Research Developments: The company announced promising results from its collaboration with Virginia Commonwealth University on Aramchol's effectiveness against drug-resistant gastrointestinal cancers, as well as significant findings from its Phase 1 AM-001 study.
Funding Activities: In 2025, Galmed raised approximately $9.3 million through equity lines and ATM facilities, contributing to its financial stability.
Strategic Focus: Galmed is concentrating on advancing Aramchol for liver disease and expanding its product pipeline to include cardiometabolic and oncological indications beyond NASH and fibrosis.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GLMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GLMD
About GLMD
Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Galmed Develops New Aramchol Formulation for CNS Diseases
- Breakthrough Drug Development: Galmed, in collaboration with Barcode Nanotech, has developed a new formulation of Aramchol that can cross the blood-brain barrier, potentially serving as a disease-modifying therapy for chronic CNS diseases like Parkinson's, addressing a significant unmet need in the market.
- Targeting Mechanism Innovation: The new formulation encapsulates Aramchol in lipid nanoparticles and is administered via subcutaneous injection, ensuring effective delivery to the brain, which could significantly improve the pathological state of Parkinson's patients and slow disease progression.
- Preclinical Research Results: In vitro studies demonstrate that Aramchol effectively down-regulates α-synuclein aggregation in a dose-dependent manner, indicating its promising potential as the first drug targeting this pathway for neurodegenerative diseases associated with α-synuclein.
- Future Clinical Plans: Galmed plans to initiate Phase 1b/2 clinical trials for Aramchol in Parkinson's patients in H2 2026, aiming to further validate its efficacy and potentially provide new treatment options for patients.
See More
Galmed Pharmaceuticals Announces Breakthrough in CNS Drug Development
- Breakthrough Drug Formulation: Galmed Pharmaceuticals, in collaboration with Barcode Nanotech, has developed a new formulation of Aramchol that penetrates the blood-brain barrier, marking a significant advancement in the treatment of Parkinson's disease and other CNS disorders, potentially addressing the current lack of effective therapies.
- Technological Innovation: This formulation utilizes lipid nanoparticles for subcutaneous injection, combined with AI analysis tools to optimize drug delivery, enhancing the targeting and efficacy of the treatment, which could significantly improve patient outcomes.
- Preclinical Data Support: Preliminary in vitro data indicates that Aramchol dose-dependently down-regulates αSyn aggregation without associated toxicity, providing strong evidence for its safety and efficacy as a potential therapeutic agent.
- Future Clinical Trial Plans: Galmed plans to initiate Phase 1b/2 clinical trials in Parkinson's patients in H2 2026, which, if successful, will introduce new treatment options in the field and further solidify the company's position in the biopharmaceutical industry.
See More
Galmed Pharmaceuticals Shares Surge 85% on New Drug Formulation Launch
- Stock Surge: Galmed Pharmaceuticals (GLMD) shares soared over 85% in pre-market trading on Thursday, surpassing $1 for the first time since December 19, indicating strong market enthusiasm for the new drug formulation and reflecting investor optimism about the company's future potential.
- New Drug Formulation: The newly launched Aramchol formulation utilizes lipid nanoparticles delivered via injection, designed to cross the blood-brain barrier, representing a significant technological breakthrough that could provide new treatment options for central nervous system disorders like Parkinson's disease, showcasing the company's innovative capabilities in biotechnology.
- Market Performance: GLMD's stock has gained 27% over the past five sessions, and the robust pre-market performance further solidifies investor confidence in the company, potentially attracting more institutional investors' interest in the stock.
- Collaborative Development: The formulation was developed in collaboration with Barcode Nanotech, highlighting Galmed's strategic partnerships in technology development aimed at addressing unmet medical needs through innovative drugs, thereby enhancing its competitive position in the market.
See More
GALMED PHARMACEUTICALS LTD CREATES BRAIN-PENETRATING ARAMCHOL FORMULATION USING BARCODE NANOTECHNOLOGY
Company Development: Galmed Pharmaceuticals Ltd has developed a brain-penetrating formulation of aaramchol using barcoded nanotech.
Innovation Focus: The new formulation aims to enhance the delivery of aaramchol to the brain, potentially improving treatment efficacy.
See More
Galmed Pharmaceuticals Receives Nasdaq Compliance Notice
- Compliance Notice: Galmed Pharmaceuticals received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1 per share, necessitating compliance restoration within 180 days until July 28, 2026.
- Restoration Requirements: The company must maintain a closing bid price of at least $1 for a minimum of 10 consecutive business days; failure to do so may allow for an additional compliance period, contingent on meeting other listing requirements.
- Stock Price Impact: Following the notice, Galmed's stock price fell by 5.33% to $0.71, reflecting market sensitivity to compliance risks and potential implications for the company's future financing capabilities.
- Trading Impact: Despite the compliance notice, Galmed stated that it has no immediate effect on its trading on the Nasdaq Capital Market, indicating the company is actively managing its listing status.
See More
Galmed Pharmaceuticals Receives Nasdaq Compliance Notice
- Compliance Notice: Galmed Pharmaceuticals received a letter from Nasdaq indicating non-compliance with the minimum bid price of $1.00 per share, requiring compliance within 180 days to avoid potential delisting risks.
- Compliance Period: The company has until July 28, 2026, to regain compliance; if the closing bid price reaches $1 for ten consecutive business days during this period, it will receive written confirmation of compliance, thus avoiding delisting.
- Market Impact: Although the notice does not immediately affect the company's Nasdaq listing, failure to regain compliance could negatively impact investor confidence and stock price.
- Strategic Development: Galmed focuses on the development of Aramchol for liver diseases and other related conditions, actively pursuing diversification of its product pipeline to address market competition.
See More
Galmed Develops New Aramchol Formulation for CNS Diseases
- Breakthrough Drug Development: Galmed, in collaboration with Barcode Nanotech, has developed a new formulation of Aramchol that can cross the blood-brain barrier, potentially serving as a disease-modifying therapy for chronic CNS diseases like Parkinson's, addressing a significant unmet need in the market.
- Targeting Mechanism Innovation: The new formulation encapsulates Aramchol in lipid nanoparticles and is administered via subcutaneous injection, ensuring effective delivery to the brain, which could significantly improve the pathological state of Parkinson's patients and slow disease progression.
- Preclinical Research Results: In vitro studies demonstrate that Aramchol effectively down-regulates α-synuclein aggregation in a dose-dependent manner, indicating its promising potential as the first drug targeting this pathway for neurodegenerative diseases associated with α-synuclein.
- Future Clinical Plans: Galmed plans to initiate Phase 1b/2 clinical trials for Aramchol in Parkinson's patients in H2 2026, aiming to further validate its efficacy and potentially provide new treatment options for patients.
See More
Galmed Pharmaceuticals Announces Breakthrough in CNS Drug Development
- Breakthrough Drug Formulation: Galmed Pharmaceuticals, in collaboration with Barcode Nanotech, has developed a new formulation of Aramchol that penetrates the blood-brain barrier, marking a significant advancement in the treatment of Parkinson's disease and other CNS disorders, potentially addressing the current lack of effective therapies.
- Technological Innovation: This formulation utilizes lipid nanoparticles for subcutaneous injection, combined with AI analysis tools to optimize drug delivery, enhancing the targeting and efficacy of the treatment, which could significantly improve patient outcomes.
- Preclinical Data Support: Preliminary in vitro data indicates that Aramchol dose-dependently down-regulates αSyn aggregation without associated toxicity, providing strong evidence for its safety and efficacy as a potential therapeutic agent.
- Future Clinical Trial Plans: Galmed plans to initiate Phase 1b/2 clinical trials in Parkinson's patients in H2 2026, which, if successful, will introduce new treatment options in the field and further solidify the company's position in the biopharmaceutical industry.
See More
Galmed Pharmaceuticals Shares Surge 85% on New Drug Formulation Launch
- Stock Surge: Galmed Pharmaceuticals (GLMD) shares soared over 85% in pre-market trading on Thursday, surpassing $1 for the first time since December 19, indicating strong market enthusiasm for the new drug formulation and reflecting investor optimism about the company's future potential.
- New Drug Formulation: The newly launched Aramchol formulation utilizes lipid nanoparticles delivered via injection, designed to cross the blood-brain barrier, representing a significant technological breakthrough that could provide new treatment options for central nervous system disorders like Parkinson's disease, showcasing the company's innovative capabilities in biotechnology.
- Market Performance: GLMD's stock has gained 27% over the past five sessions, and the robust pre-market performance further solidifies investor confidence in the company, potentially attracting more institutional investors' interest in the stock.
- Collaborative Development: The formulation was developed in collaboration with Barcode Nanotech, highlighting Galmed's strategic partnerships in technology development aimed at addressing unmet medical needs through innovative drugs, thereby enhancing its competitive position in the market.
See More
GALMED PHARMACEUTICALS LTD CREATES BRAIN-PENETRATING ARAMCHOL FORMULATION USING BARCODE NANOTECHNOLOGY
Company Development: Galmed Pharmaceuticals Ltd has developed a brain-penetrating formulation of aaramchol using barcoded nanotech.
Innovation Focus: The new formulation aims to enhance the delivery of aaramchol to the brain, potentially improving treatment efficacy.
See More
Galmed Pharmaceuticals Receives Nasdaq Compliance Notice
- Compliance Notice: Galmed Pharmaceuticals received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement of $1 per share, necessitating compliance restoration within 180 days until July 28, 2026.
- Restoration Requirements: The company must maintain a closing bid price of at least $1 for a minimum of 10 consecutive business days; failure to do so may allow for an additional compliance period, contingent on meeting other listing requirements.
- Stock Price Impact: Following the notice, Galmed's stock price fell by 5.33% to $0.71, reflecting market sensitivity to compliance risks and potential implications for the company's future financing capabilities.
- Trading Impact: Despite the compliance notice, Galmed stated that it has no immediate effect on its trading on the Nasdaq Capital Market, indicating the company is actively managing its listing status.
See More
Galmed Pharmaceuticals Receives Nasdaq Compliance Notice
- Compliance Notice: Galmed Pharmaceuticals received a letter from Nasdaq indicating non-compliance with the minimum bid price of $1.00 per share, requiring compliance within 180 days to avoid potential delisting risks.
- Compliance Period: The company has until July 28, 2026, to regain compliance; if the closing bid price reaches $1 for ten consecutive business days during this period, it will receive written confirmation of compliance, thus avoiding delisting.
- Market Impact: Although the notice does not immediately affect the company's Nasdaq listing, failure to regain compliance could negatively impact investor confidence and stock price.
- Strategic Development: Galmed focuses on the development of Aramchol for liver diseases and other related conditions, actively pursuing diversification of its product pipeline to address market competition.
See More
